Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients

May 30, 2014

Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs.

All of the 31 included in the study received a combination of gemcitabine and cisplatin, two drugs normally administered for 12 weeks before to remove the tumors. This became the standard of care after one study looked back, retrospectively, at a their experience with a group of patients who had already received the drugs over 12 weeks and found that more than one-quarter saw their tumors disappear before surgery. Although this is the standard of care, no one had yet followed a group of patients taking these drugs from the start—known as a "prospective" study—which is the best way to test how well the treatment works and to uncover any issues, said Dr. Plimack.

"It's important to prospectively investigate both the activity and the potential side effects of these two in patients with bladder cancer," said Elizabeth R. Plimack, MD, MS, Attending Physician the Department of Medical Oncology at Fox Chase Cancer, who reported these findings during the 50th Annual Meeting of the American Society of Clinical Oncology. "In patients who may be cured of their cancers, that cause and other complications may delay or prevent life-saving surgery."

In Dr. Plimack's study, she and her colleagues gave patients gemcitabine and cisplatin over 6 weeks, rather than the usual 12. "Hitting tumors with chemotherapy more frequently might be more effective, and for patients who don't respond, a shorter regimen causes less of a delay in surgery," said Dr. Plimack, "and patients spend less of their life in cancer treatment."

But Dr. Plimack and her colleagues had to stop the phase II clinical trial before it was complete after 7 patients (23%) experienced serious cardiovascular events such as stroke, , and potentially deadly blood clots in the lungs or legs.

Even though gemcitabine is known to increase the risk of cardiovascular problems, she and her colleagues were "surprised" to see so many patients were affected. It's possible that condensing the doses into 6 weeks caused problems, but that's not the only explanation, said Dr. Plimack. "Two of the most severe cardiovascular events occurred after one treatment, so the dosing schedule was not the only factor here."

Gemcitabine is a frequently administered drug, so it is critical that researchers continue to follow patients receiving it, said Dr. Plimack. "In the meantime, patients who have concerns about taking gemcitabine should consult their doctors about their individual plan."

Explore further: Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer

Related Stories

Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer

May 17, 2012
For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery. A large ...

More patients with ovarian cancer are receiving chemotherapy before surgery

May 30, 2014
The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis from Fox Chase Cancer Center that will be presented ...

Chemotherapy before or after surgery for high-risk bladder cancer improves survival, but is not routinely administered

April 14, 2014
Contrary to treatment guidelines for high-risk bladder cancer, chemotherapy before or after surgery is not commonly used in routine clinical practice. The findings are published early online in Cancer, a peer-reviewed journal ...

Getting chemo first may help in rectal cancer

May 15, 2014
(Medical Xpress)—A new phase II study to be presented at the annual meeting of the American Society for Clinical Oncology finds that if chemotherapy is offered before radiation and surgery, more patients will be able to ...

Radioimmunotherapy, Gemcitabine combination shows early promise for metastatic pancreatic ductal cancer

May 20, 2014
A combination of several small doses of an investigational radioimmunotherapy and the chemotherapy gemcitabine had superior outcomes compared with radioimmunotherapy alone in patients with metastatic pancreatic ductal cancer, ...

Study finds CT scans predict chemotherapy response in pancreatic cancer

March 11, 2014
Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research from The University of Texas MD Anderson Cancer Center, the ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.